Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine

Fri Apr 19 13:40:18 2024

(2022) Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine. Iranian journal of pathology. pp. 448-460. ISSN 1735-5303 (Print) 2345-3656 (Electronic) 1735-5303 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/36532644

Abstract

BACKGROUND & OBJECTIVE: The vaccine available to prevent Hepatitis B virus disease is ineffective in 5 of people due to the use of HBsAg as a weak immunogenic factor. In the present study, PreS2/S fused to C18-27 peptide fragment as an effective antigen and is proposed as a promising vaccine candidate compared with the conventional vaccine prescribed in the vaccination program. METHODS: After the synthesis of PreS2/S genes and C18-27 peptide fragment in pET28a, the recombinant protein was confirmed by Western blotting. The efficacy of the PreS2/S-C18-27 protein was compared with the conventional vaccine injected into five groups of rats. Finally, the cytokine level of IF-r, IL-2, IL-4, IL-10, TNF-a, IgG1, and IgG2a were measured using the ELISA method. RESULTS: This study showed no significant difference between the recombinant vaccine group and PBS control group in the IF-r test, but there was a significant difference between groups testing IL-2 and IL-10. In addition, the group receiving the recombinant vaccine with CPG adjuvant at a dilution of 1/10 in the IgG total test on days 14 and 45 after the first injection showed a significant difference in comparison with other groups. CONCLUSION: This study showed no statistically significant difference between the recombinant protein vaccine group and the conventional vaccine group. The Th1- mediated immune responses obtained from recombinant proteins with and without CPG performed better than conventional vaccines, possibly due to the functional deficiency of the available vaccines.

Item Type: Article
Creators:
CreatorsEmail
Gholami Parizad, E.UNSPECIFIED
Imani Fooladi, A. A.UNSPECIFIED
Sedighian, H.UNSPECIFIED
Behzadi, E.UNSPECIFIED
Valizadeh, A.UNSPECIFIED
Khosravi, A.UNSPECIFIED
Keywords: CpG 7909 Hepatitis B Core Antigen Hepatitis B Vaccines Hepatitis B Virus preS2HBsAg
Divisions:
Page Range: pp. 448-460
Journal or Publication Title: Iranian journal of pathology
Journal Index: Pubmed
Volume: 17
Number: 4
Identification Number: https://doi.org/10.30699/IJP.2022.553785.2896
ISSN: 1735-5303 (Print) 2345-3656 (Electronic) 1735-5303 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4271

Actions (login required)

View Item View Item